BALLERUP, Denmark, & MADISON, N.J. — (BUSINESS WIRE) — LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of t…
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
BALLERUP, Denmark, & MADISON, N.J. — (BUSINESS WIRE) — LEO Pharma A/S, a global leader in medical dermatology, today announced results on the long-term safety and efficacy profile of t…